Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

NCT00080535 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

NIH

Sponsor class

Conditions

Lymphoma
T-Cell
Cutaneous

Interventions

BIOLOGICAL: LMB-2

Sponsor

National Cancer Institute (NCI)